Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – October 14, 2020 @ 4:00pm

OHCA Webinar
Register for the meeting here:
https://odot.webex.com/odot/onstage/g.php?MTID=e973874cb6c1bfb2c6618a3c5c2d8712a

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

Telephone Conference Participants

DUR Board Members:

Dr. Stephen Anderson –	participating via Webex Teleconference
Dr. Jennifer de los Angeles –	participating via Webex Teleconference
Ms. Jennifer Boyett –	participating via Webex Teleconference
Dr. Markita Broyles –	participating via Webex Teleconference
Dr. Theresa Garton –	participating via Webex Teleconference
Dr. Megan Hanner –	participating via Webex Teleconference
Dr. Lynn Mitchell –	participating via Webex Teleconference
Dr. John Muchmore –	participating via Webex Teleconference
Dr. Lee Muñoz –	participating via Webex Teleconference
Dr. James Osborne –	participating via Webex Teleconference

Public Access to Meeting via Webex:

Register at:
https://odot.webex.com/odot/onstage/g.php?MTID=e973874cb6c1bfb2c6618a3c5c2d8712a

Or join by phone:

Dial: +1-415-655-0002

Event number: 133 077 4146
Event password: OHCA

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting www.okhca.org/DUR and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to *DURPublicComment@okhca.org*. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. September 9, 2020 DUR Minutes – Vote
B. September 9, 2020 DUR Recommendations Memorandum

Items to be presented by Dr. Adams, Dr. Daniel, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Fall 2020 Pipeline Update – See Appendix B

A. Pharmacy Helpdesk Activity for September 2020
B. Medication Coverage Activity for September 2020
C. Fall 2020 Pipeline Update

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Adakveo® (Crizanlizumab-tmca), Oxbryta® (Voxelotor), and Reblozyl® (Luspatercept-aamt) – See Appendix C

A. Introduction
B. New U.S. Food and Drug Administration (FDA) Approval(s)
C. College of Pharmacy Recommendations

Items to be presented by Dr. Baxley, Dr. Borders, Dr. Schmidt, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Enhertu® (Fam-Trastuzumab Deruxtecan-nxki), Phesgo™ (Pertuzumab/Trastuzumab/Hyaluronidase-zzxf), Trodelvy™ (Sacituzumab Govitecan-hziy), and Tukysa™ (Tucatinib) – See Appendix D

A. New U.S. Food and Drug Administration (FDA) Approval(s) and Indication(s)
B. Product Summaries
C. Recommendations

Items to be presented by Dr. Baxley, Dr. Borders, Dr. Schmidt, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Rubraca® (Rucaparib) – See Appendix E

A. New U.S. Food and Drug Administration (FDA) Approval(s) and Indication(s)
B. Rubraca® (Rucaparib) Product Summary
C. Recommendations

Items to be presented by Dr. Baxley, Dr. Borders, Dr. Schmidt, Dr. Muchmore, Chairman:

8. Annual Review of Ovarian Cancer Medications and 30-Day Notice to Prior Authorize Zejula® (Niraparib) – See Appendix F

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Ovarian Cancer Medications
D. Prior Authorization of Ovarian Cancer Medications
E. Market News and Updates
F. Zejula® (Niraparib) Product Summary
G. Recommendations
H. Utilization Details of Ovarian Cancer Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. Annual Review of Spinal Muscular Atrophy (SMA) Medications and 30-Day Notice to Prior Authorize Evrysdi™ (Risdiplam) – See Appendix G

A. Current Prior Authorization Criteria
B. Utilization of SMA Medications
C. Prior Authorization of SMA Medications

D. Market News and Updates
E. Evrysdi™ (Risdiplam) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of SMA Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

10. Annual Review of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and 30-Day Notice to Prior Authorize Trikafta® (Elexacaftor/Tezacaftor/ Ivacaftor and Ivacaftor) – See Appendix H

A. Current Prior Authorization Criteria
B. Utilization of CFTR Modulators
C. Prior Authorization of CFTR Modulators
D. Market News and Updates
E. Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of CFTR Modulators

Items to be presented by Dr. Ford, Dr. Muchmore, Chairman:

11. Annual Review of Hepatitis C Medications and 30-Day Notice to Prior Authorize Epclusa® (Sofosbuvir/Velpatasvir) 200mg/50mg Tablet – See Appendix I

A. Introduction
B. Current Prior Authorization Criteria
C. Trends of Hepatitis C Medication Utilization
D. Hepatitis C Summary Statistics for Treated Members
E. Utilization of Hepatitis C Medications
F. Prior Authorization of Hepatitis C Medications
G. Market News and Updates
H. Regimen Comparison
I. College of Pharmacy Recommendations
J. Utilization Details of Hepatitis C Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

12. 30-Day Notice to Prior Authorize Cystadrops® (Cysteamine 0.37% Ophthalmic Solution) and Cystaran™ (Cysteamine 0.44% Ophthalmic Solution) – See Appendix J

A. Introduction
B. Product Comparison
C. College of Pharmacy Recommendations
D. Utilization Details of Cystaran™ (Cysteamine 0.44% Ophthalmic Solution)

Items to be presented by Dr. Daniel, Dr. Muchmore, Chairman:

13. Annual Review of Signifor® LAR (Pasireotide) and 30-Day Notice to Prior Authorize Mycapssa® (Octreotide) – See Appendix K

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Signifor® LAR (Pasireotide)
D. Prior Authorization of Signifor® LAR (Pasireotide)
E. Market News and Updates
F. Mycapssa® (Octreotide) Product Summary
G. College of Pharmacy Recommendations

Non-Presentation/Questions Only:

14. Annual Review of Lambert-Eaton Myasthenic Syndrome (LEMS) Medications [Firdapse® (Amifampridine) and Ruzurgi® (Amifampridine)] – See Appendix L

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of LEMS Medications
D. Prior Authorization of LEMS Medications
E. Market News and Updates
F. College of Pharmacy Recommendations
G. Utilization Details of LEMS Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

15. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix M

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

16. Future Business* (Upcoming Product and Class Reviews)

Due to the Veterans' Day holiday, the November DUR meeting will be held on the first Wednesday of the month on November 4, 2020.

A. Targeted Immunomodulator Agents
B. Constipation and Diarrhea Medications
C. Atopic Dermatitis Medications
D. Anticoagulants and Platelet Aggregation Inhibitors

**Future business subject to change.*

17. Adjournment